This study will evaluate the safety, tolerability, and efficacy of ABBV-3067 given alone and in combination with various doses of ABBV-2222 in adults with Cystic Fibrosis who are homozygous for the F508del mutation.

• Inclusion Criteria :
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
  • Confirmed clinical diagnosis of Cystic Fibrosis (CF) who are homozygous for the F508del CF transmembrane conductance regulator (CFTR) mutation
  • Stable pulmonary status
  • Lung function 40% - 90% of predicted normal for age, gender and height at screening
• Exclusion Criteria :
  • History of solid organ or hematopoietic transplant
  • Cirrhosis with portal hypertension
  • Use of CFTR modulator therapy within 60 days prior to Screening
• Study start date : December 11, 2019
• Study end date : October 22, 2022
• Wales-Based Study Contact : Please speak to your clinician
• Principal Investigator : ABBVIE INC

Contact details

Cardiff & Vale University Health Board, School of Medicine, UHW Main Building Heath Park Campus CardiffCardiff,CF14 4XN abbvieclinicaltrials@abbvie.com